Skip to main content
Cyber Week Sale - Get 40% off Vantage
Get Started
SubscribeLogin
Published • loading... • Updated

J&J Gets EU Approval for Imaavy in gMG

Summary by Pharmaphorum
J&J's Imaavy has become the first FcRn blocker to be approved in the EU for both adolescent and adult patients with generalised myasthenia gravis

2 Articles

PharmaphorumPharmaphorum
Center

J&J gets EU approval for Imaavy in gMG

J&J's Imaavy has become the first FcRn blocker to be approved in the EU for both adolescent and adult patients with generalised myasthenia gravis

Read Full Article
myastheniagravisnews.commyastheniagravisnews.com

Imaavy approved in EU to treat gMG in both adolescents and adults

Imaavy, now approved in the European Union to treat generalized myasthenia gravis, is the first FcRn blocker cleared for use by adolescents.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Pharmaphorum broke the news in on Tuesday, December 2, 2025.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Johnson & Johnson icon

Johnson & Johnson

European Union icon

European Union

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal